Black Cohosh (Cimicifuga racemosa)

Black cohosh (Cimicifuga racemosa) contains triterpene glycosides, particularly actein and 23-epi-26-deoxyactein, as its primary bioactive compounds. These constituents are thought to modulate serotonergic and dopaminergic pathways in the hypothalamus to reduce thermoregulatory dysfunction associated with menopause.

Origin & History

Black cohosh (Cimicifuga racemosa) is a perennial herb native to North America, primarily sourced from the rhizomes and roots of the plant, also known as Actaea racemosa. It is typically extracted using isopropanolic methods to produce standardized dry extracts containing triterpene glycosides as primary constituents.

Historical & Cultural Context

Black cohosh has been used in Native American traditional medicine for women's health issues, including menopausal symptoms, for centuries. Modern standardized monopreparations stem from this traditional context for perimenopausal and postmenopausal relief.

Health Benefits

• May reduce menopausal vasomotor symptoms (hot flashes, night sweats) - supported by mixed RCT evidence with some positive results at 4-8 weeks
• Potentially improves psychiatric symptoms during menopause - one RCT showed reductions in Green Climacteric Scale psychiatric subscale scores
• May support physical comfort during menopause - evidence from RCTs showing improvements in physical symptom subscales
• Possibly helps menopausal symptoms in breast cancer patients on tamoxifen - preliminary evidence from recent reviews (2022-2023)
• Shows good liver safety profile - meta-analysis of 5 RCTs (n=1,117) found no hepatotoxicity over 3-6 months

How It Works

Black cohosh triterpene glycosides, including actein and cimiracemoside A, do not bind estrogen receptors (ER-alpha or ER-beta) at physiologically relevant concentrations, refuting earlier estrogenic theories. Current evidence suggests these compounds act as selective serotonin reuptake modulators and bind to 5-HT1A, 5-HT1D, and 5-HT7 receptors in the hypothalamic thermoregulatory center, dampening vasomotor instability. Additionally, dopaminergic activity via D2 receptor partial agonism and inhibition of monoamine oxidase (MAO) may contribute to reductions in luteinizing hormone (LH) surges linked to hot flash episodes.

Scientific Research

A 2012 Cochrane review analyzed 16 RCTs (n=2,027 perimenopausal/postmenopausal women) using median 40 mg daily for 23 weeks, though results were mixed (PMID not provided). A 2009 double-blind RCT (n=28) found no significant anxiety reduction versus placebo (PMID:19745648), while a 2011 meta-analysis of 5 RCTs (n=1,117) confirmed safety with no liver enzyme elevations. Recent reviews (PMIDs:35403534, 37192826) suggest potential benefits but call for more rigorous trials.

Clinical Summary

Multiple randomized controlled trials (RCTs) have examined standardized black cohosh extract (most commonly Remifemin, 40 mg/day) over 4–24 weeks in peri- and postmenopausal women. A 2012 Cochrane-style meta-analysis of 16 trials found modest but statistically significant reductions in hot flash frequency (approximately 26% versus placebo), though heterogeneity across studies was high. One RCT (n=120) demonstrated significant improvement on the Green Climacteric Scale psychiatric subscale compared to placebo, suggesting mood-related benefits. Overall evidence is rated as moderate quality due to small sample sizes, short durations, and variability in extract standardization.

Nutritional Profile

Black Cohosh is a medicinal root/rhizome, not a nutritional food source; macronutrient content is negligible in typical supplemental doses (standardized extracts of 20-40mg dried rhizome equivalent per tablet). Primary bioactive compounds include: Triterpene glycosides (actein, 23-epi-26-deoxyactein, cimicifugoside) at approximately 2.5% w/w in standardized extracts — the 27-deoxyactein fraction is considered the principal marker compound; Phenolic acids including caffeic acid, isoferulic acid, and fukinolic acid (combined ~0.1-0.5% in dried root); Formononetin, an isoflavone-like compound, detected in some but not all preparations (trace to ~0.04% depending on extraction method — its presence remains debated in current literature); Cimiracemate A and B (hydroxycinnamic acid esters) contributing to antioxidant activity; Alkaloids including N-methylcytisine in trace amounts (<0.01%); Resin compounds (cimicifugin/macrotin) at approximately 6-7% of dried root. Micronutrient content in supplement doses is pharmacologically insignificant — no meaningful contribution to dietary vitamins or minerals. Fiber content in whole root preparations is present but negligible at supplemental doses. Bioavailability notes: Triterpene glycosides demonstrate moderate oral bioavailability; fat-soluble fractions benefit from co-administration with food; isopropanolic extracts (used in Remifemin, the most studied commercial preparation) show consistent standardization at 1mg 27-deoxyactein per 20mg tablet.

Preparation & Dosage

Clinically studied doses range from 40-128 mg daily of isopropanolic dry extract (standardized to 2.5-5% triterpene glycosides) for 3-12 months. The most common dose in trials is 40 mg daily. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Red clover, evening primrose oil, vitamin E, calcium, magnesium

Safety & Interactions

Black cohosh is generally well tolerated at standard doses (40–128 mg/day of standardized extract) with the most common adverse effects being mild gastrointestinal upset and headache. Rare but serious cases of hepatotoxicity have been reported, prompting the EMA and USP to recommend liver function monitoring with prolonged use; patients with pre-existing liver disease should avoid it. It may interact with tamoxifen by potentially competing for CYP2D6 metabolism, and caution is warranted in patients on antihypertensives due to additive hypotensive effects. Black cohosh is contraindicated in pregnancy due to potential uterotonic activity and should be used under medical supervision in hormone-sensitive conditions, despite its non-estrogenic mechanism.